𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models

✍ Scribed by Stegeman, Hanneke; Kaanders, Johannes H.; van der Kogel, Albert J.; Iida, Mari; Wheeler, Deric L.; Span, Paul N.; Bussink, Johan

Book ID
122995307
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
946 KB
Volume
106
Category
Article
ISSN
0167-8140

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sequence dependence of cell growth inhib
Sequence dependence of cell growth inhibition by EGFR–tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer
✍ Carmen M. Klass; Mi Sun Choe; Selwyn J. Hurwitz; Mourad Tighiouart; Xin Zhang; Z πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 393 KB

## Abstract ## Background This study was to explore whether the efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Z, Iressa, gefitinib) plus chemotherapeutic agents docetaxel (D) and cisplatin (P) may benefit from sequencing of the combination. ## Methods

Inhibition of proliferation and inductio
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (β€˜Iressa’) is independent of EGFR expression level
✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 297 KB πŸ‘ 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant